Trader: Low Volume ...
Cyclacel Pharmaceuticals Inc. (CYCC: NASDAQ)
$0.52 -0.07 | -11.86%
06/04/12 - 03:59 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 2.15 | 0.58 | 0.98 |
| Price to Sales (TTM) | 52.11 | 4.62 | 1.42 |
| Price to Book (MRQ) | 1.88 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 1.88 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -2.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -2.50 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -16.10 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 1.90 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 28.17 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -73.41 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.50 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.70 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 73.40 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -4,402.24 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -20.37 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -53.70 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -64.50 | 2.20 | 2.50 |
| Return on Investment (TTM) | -73.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -89.80 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 37,111.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -756,111.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 1.60 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with CYCC
- Portfolio NameUser Type
- Uservlady 1
- Contributor13 Biotech Stocks Bought an...
- ProWilbur Ross - Invesco Priva...
- Contributor10 Cheap Biotech Stocks Tha...
- Userjeezlola
- Contributor10 Biotech Stocks Expected ...
- UserJSD Holdings
- UserBesV Portfolio 1
- UserStock2009
- UserTdawg
Latest CYCC Headlines from TheStreet
- Friday's Top 10 Articles, Videos on TheStreet 03.02.12 | 01:03 pm
- Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash 03.02.12 | 05:03 am
- BIO CEO Conference Live Blog 02.13.12 | 01:02 pm
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling 11.16.11 | 08:11 am
- Biotech Stock Mailbag: Somaxon, Transcept 10.07.11 | 06:10 am
- Biotech Stock Mailbag: Research Backs Shorting Micro-Cap Cancer Drug Stocks 09.30.11 | 05:09 am
- Biotech Stock Mailbag: Cyclacel Pharma 08.12.11 | 05:08 am
- Cyclacel Stock Gaps Down On Today's Open (CYCC) 08.08.11 | 10:08 am
- Biotech Stock Mailbag: Ranking Cheap Biotechs 07.01.11 | 08:07 am
Press Releases for CYCC
Partner Headlines for CYCC
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Cyclacel: An Intriguing Long Shot - Seeking Alpha 03.20.12 | 08:03 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.18.11 | 09:11 am
- Buy And Sell Ideas Based On Wednesday's Big News And Price Decliners - Seeking Alpha 09.29.11 | 08:09 am
- The Biotech Bump: Cyclacel Pharmaceuticals - Benzinga 07.28.11 | 01:07 pm
- Profit From These 3 Analysts' Stock Picks for Under $10 - Seeking Alpha 07.13.11 | 09:07 am
- Cyclacel Pharmaceuticals Files S-3 $75M Mixed Securities Shelf - Benzinga 04.04.11 | 04:04 pm
- US scientists recreate heart defect in a lab dish - Reuters 02.09.11 | 01:02 pm
- Pfizer, Adolor End Collaboration to Develop Pain Meds: Biotech's Latest Troubles - Seeking Alpha 12.26.10 | 01:12 am





